Jul. 2005

Clinical Pharmacokinetics

Population Pharmacokinetics

Pharmacokinetic/Pharmacodynamic Analysis

modeling & simulation

Pharmacometrics

Pharmacodynamics

Pharmacokinetics

Life sciences, Clinical pharmacy

Apr. 2025 - Present
Nihon University, School of Pharmacy, 教授

Apr. 1992 - Mar. 2025
塩野義製薬株式会社, 研究開発, 臨床薬理

Oct. 2005 - Oct. 2006
Stanford University, School of Medicine, Postdoctoral Fellow

Apr. 2004 - Mar. 2005
Kyoto University, 医学部附属病院 薬剤部, 研究生

Apr. 1990 - Mar. 1992
富山医科薬科大学大学院, 薬学研究科博士前期課程

Apr. 1985 - Mar. 1990
富山医科薬科大学, 薬学部・薬科学科

Jan. 2011 - Present

Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity
Toru Ishibashi; Hideki Tanioka; Tatsuya Ikehara; Safwan Kezbor; Takuhiro Sonoyama
Clinical Drug Investigation, Feb. 2025

Population Pharmacokinetics of Ensitrelvir in Healthy Participants and Participants with SARS-CoV-2 Infection in the SCORPIO-SR Study
Toru Ishibashi; Ryosuke Shimizu; Ryuji Kubota
Clinical Pharmacokinetics, Dec. 2024

Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial.
Simon Portsmouth; Frederick G Hayden; Keiko Kawaguchi; Toru Ishibashi; Masahiro Kinoshita; Takao Shishido; Kenji Tsuchiya; Takeki Uehara
Journal of the Pediatric Infectious Diseases Society, Apr. 2021

Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
Yoshinori Ando; Takeshi Noshi; Kenji Sato; Toru Ishibashi; Yuki Yoshida; Takahiro Hasegawa; Motoyasu Onishi; Mitsutaka Kitano; Ryoko Oka; Makoto Kawai; Ryu Yoshida; Akihiko Sato; Takao Shishido; Akira Naito
The Journal of antimicrobial chemotherapy, Jan. 2021

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes.
Nobuo Hirotsu; Hiroki Sakaguchi; Chisako Sato; Toru Ishibashi; Keiko Baba; Shinya Omoto; Takao Shishido; Kenji Tsuchiya; Frederick G Hayden; Takeki Uehara; Akira Watanabe
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Aug. 2020

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
Takato Yokoyama; Hiroki Sakaguchi; Toru Ishibashi; Takao Shishido; Pedro A Piedra; Chisako Sato; Kenji Tsuchiya; Takeki Uehara
The Pediatric infectious disease journal, Aug. 2020

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications.
Hiroki Koshimichi; Sylvie Retout; Valerie Cosson; Vincent Duval; Stefan De Buck; Yoshiyuki Tsuda; Toru Ishibashi; Toshihiro Wajima
Antimicrobial agents and chemotherapy, Jun. 2020

Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
Kazuya Fukumura; Nao Kawaguchi; Toru Ishibashi; Ryuji Kubota; Yukio Tada; Eriko Ogura
Clinical Drug Investigation, Jun. 2020

Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus
Keiko Baba; Ryoko Oka; Shinya Shano; Shinya Omoto; Takeshi Noshi; Takao Shishido; Akira Naito; Keiko Kawaguchi; Toru Ishibashi; Takeki Uehara
Influenza and Other Respiratory Viruses, May 2020

Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
Yumiko Matsuo; Toru Ishibashi; Sayaka Matsumoto; Takayuki Katsube; Toshihiro Wajima
Journal of pharmaceutical sciences, Sep. 2019

Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients.
Hiroki Koshimichi; Toru Ishibashi; Toshihiro Wajima
Journal of pharmaceutical sciences, Sep. 2019

Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.
Hiroki Koshimichi; Yoshiyuki Tsuda; Toru Ishibashi; Toshihiro Wajima
Journal of pharmaceutical sciences, May 2019

Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
Akira Watanabe; Tadashi Ishida; Nobuo Hirotsu; Keiko Kawaguchi; Toru Ishibashi; Takao Shishido; Chisako Sato; Simon Portsmouth; Kenji Tsuchiya; Takeki Uehara
Antiviral research, Mar. 2019

Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.
Hiroki Koshimichi; Toru Ishibashi; Nao Kawaguchi; Chisako Sato; Akira Kawasaki; Toshihiro Wajima
Clinical drug investigation, Dec. 2018

Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.
Nao Kawaguchi; Hiroki Koshimichi; Toru Ishibashi; Toshihiro Wajima
Clinical drug investigation, Nov. 2018

Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
Yutaka Saisho; Toru Ishibashi; Hidenori Fukuyama; Hiroyuki Fukase; Jingoro Shimada
Antiviral therapy, 2017

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.
Takayuki Katsube; Toshihiro Wajima; Toru Ishibashi; Juan Camilo Arjona Ferreira; Roger Echols
Antimicrobial agents and chemotherapy, Jan. 2017

Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.
Takayuki Katsube; Toru Ishibashi; Takeshi Kano; Toshihiro Wajima
Clinical pharmacokinetics, Nov. 2016

Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia
Fukumori S.; Tsuji Y.; Mizoguchi A.; Kasai H.; Ishibashi T.; Iwamura N.
Journal of Clinical Pharmacy and Therapeutics, May 2016, Refereed

クレストールOD錠の開発
林健太郎; 野綱誠; 田中里可子; 石橋徹; 福山秀宣
新薬と臨牀, Mar. 2016, Refereed

Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.
Yumiko Matsuo; Toru Ishibashi; Alan S Hollister; Toshihiro Wajima
Antimicrobial agents and chemotherapy, Nov. 2015

Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients.
Yumiko Matsuo; Toru Ishibashi; Kenji Shimamura; Toshihiro Wajima
Journal of pharmaceutical sciences, Sep. 2015

Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment.
Yumiko Matsuo; Toru Ishibashi; Ryuji Kubota; Toshihiro Wajima
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Feb. 2015

Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.
Norio Sugaya; Shigeru Kohno; Toru Ishibashi; Toshihiro Wajima; Takao Takahashi
Antimicrobial agents and chemotherapy, Jan. 2012

The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
Ivy Song; Sherene S Min; Julie Borland; Yu Lou; Shuguang Chen; Parul Patel; Toru Ishibashi; Stephen C Piscitelli
Journal of clinical pharmacology, Feb. 2011

Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects.
Ivy Song; Sherene S Min; Julie Borland; Yu Lou; Shuguang Chen; Toru Ishibashi; Toshihiro Wajima; Stephen C Piscitelli
Journal of acquired immune deficiency syndromes (1999), Nov. 2010

Evaluation of Bayesian predictability of vancomycin concentration using population pharmacokinetic parameters in pediatric patients.
Ayako Ohnishi; Yoshitaka Yano; Toru Ishibashi; Takayuki Katsube; Takayoshi Oguma
Drug metabolism and pharmacokinetics, Dec. 2005

Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Toru Ishibashi; Yoshitaka Yano; Takayoshi Oguma
Anticancer research, 2005

Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion.
Toru Ishibashi; Kazuya Fukumura; Yoshitaka Yano; Takayoshi Oguma
Anticancer research, 2005

Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.
Toru Ishibashi; Yoshitaka Yano; Takayoshi Oguma
British journal of clinical pharmacology, Aug. 2003

Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment.
Tamae Hamaki; Masahiro Kami; Masahiro Igarashi; Eiji Kusumi; Yasuji Arase; Toru Ishibashi; Kenji Shimamura; Shigesaburo Miyakoshi; Shin-Ichi Morinaga; Yoichi Takaue; Masahiro Hayashi; Yoshitomo Mutou
Leukemia & lymphoma, Apr. 2003

A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients
Ishibashi T.; Yano Y.; Oguma T.
Cancer Chemotherapy and Pharmacology, Sep. 2002, Refereed
Lead

Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats
Ishibashi T.; Yano Y.; Oguma T.
Journal of Pharmacy and Pharmacology, Mar. 2000, Refereed
Lead

Pharmacokinetics of S-309309, a Novel SelectiveInhibitor of Monoacylglycerol Acyltransferase 2
Toru Ishibashi; Hideki Tanioka; Safwan Kezbor; Gillette NJ; Takuhiro Sonoyama
Obesity, Nov. 2023, Not refereed
Lead

530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
Toru Ishibashi; Luna Nomura; Ryosuke Shimizu; Ryuji Kubota
Open Forum Infectious Diseases, Nov. 2023, Not refereed
Lead

新規抗肥満薬であるMGAT2阻害剤S-309309の安全性,忍容性及び薬物動態に関する第1相臨床試験
園山 拓洋; 石橋 徹; Kezbor Safwan; 谷岡 秀樹
肥満研究, Nov. 2023, Not refereed

バロキサビルマルボキシル代謝物における薬物動態の人種間差に対する遺伝子多型の影響
柴田 理沙; 川口 菜穂; 窪田 竜二; 越道 大樹; 石橋 徹; 輪嶋 恵宏
日本臨床薬理学会学術総会抄録集42回, Dec. 2021, Not refereed

Open-label study to evaluate the efficacy, safety, and pharmacokinetics of switching from oxycodone hydrochloride tablets to S-8117OTR in patients with chronic pain
KAWAMATA Mikito; SASAKI Takuma; ISHIDA Mitsuhiro; ISHIBASHI Toru; HIDA Hideaki; KIKUCHI Shin-ichi
Journal of Japan Society of Pain Clinicians, 25 Jun. 2021

1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications
Hiroki Koshimichi; Sylvie Retout,Valérie F Cosson; Stefan De Buck; Yoshiyuki Tsuda; Toru Ishibashi; Toshihiro Wajima
Open Forum Infectious Diseases, Oct. 2019, Not refereed

A Phase 1 Study of Safety, Tolerability and Pharmacokinetics of Oral Single-Dose S-033188, a Novel Anti-influenza Agent, in Healthy Adult Male Subjects
Akira Kawasaki; Chisako Sato; Toru Ishibashi
Open Forum Infectious Diseases, Dec. 2016
Last

S-649266 Modeling and Simulation for Prediction of Efficacy and Dose Optimization
Takayuki Katsube; Toru Ishibashi; David Tenero; Toshihiro Wajima
Open Forum Infectious Diseases, Dec. 2014, Not refereed

小児通年性アレルギー鼻炎患者におけるロラタジンのPopulation Pharmacokinetics(Population Pharmacokinetics of Loratadine in Pediatric Patients with Perennial Allergic Rhinitis)
谷川原 祐介; 石橋 徹; 石川 研介; 吉岡 隆之
日本小児臨床薬理学会雑誌, Dec. 2012, Not refereed

ドリペネムの母集団薬物動態解析及びモンテカルロシミュレーションによる腎機能障害者における用法用量の検討
石橋 徹; 松尾 裕美子; 窪田 竜二; 輪嶋 恵
TDM研究, May 2012, Not refereed
Lead

抗インフルエンザ薬ペラミビルの母集団薬物動態パラメータに基づく、腎機能障害患者における用量の検討
松尾 裕美子; 輪嶋 恵宏; 石橋 徹; 河野 茂; 嶋田 甚五郎
日本化学療法学会雑誌, Nov. 2010, Not refereed

バンコマイシンの適正使用におけるTDM実施の有用性 シオノギVCM-TDM解析支援ソフトウェアを用いて
石橋徹; 勝部孝行; 幡野玲子
広島県病院薬剤師会誌, Aug. 2007, Not refereed, Invited
Lead

日本人小児患者におけるバンコマイシン母集団パラメータ予測性評価
大西 綾子; 矢野 義孝; 石橋 徹; 勝部 孝行; 尾熊 隆嘉
TDM研究, Apr. 2006, Not refereed

NONMEMを活用したTDM解析支援ソフトウェアの開発
石橋 徹; 矢野 育子; 増田 智先; 桂 敏也; 乾 賢一
TDM研究, Apr. 2006
Lead

1-compartment modelによるバンコマイシン母集団薬物動態パラメータの算出
小笠原 拓也; 五十嵐 正博; 石橋 徹; 大西 綾子; 中谷 龍王; 中田 紘一郎; 吉村 邦彦; 田口 恭治
日本薬学会年会要旨集124年会, Mar. 2004, Not refereed

白金錯体抗癌剤ネダプラチン (アクプラ) の母集団体内動態解析
石橋 徹; 矢野 義孝; 尾熊 隆嘉
臨床薬理, Apr. 2001, Not refereed
Lead

Nedaplatin(254S)dosage Prospective study of new formula
内藤 子来; 安達 進; 脇本 栄子; 小笠原 利忠; 竹村 正; 香山 浩二; 伊藤 公彦; 井谷 嘉男; 石橋 徹; 尾熊 隆嘉
日本癌治療学会誌, Oct. 1999, Not refereed

A pharmacokinetic study of nedaplatin(254S)
安達 進; 脇本 栄子; 金澤 理一郎; 小笠原 利忠; 竹村 正; 香山 浩二; 伊藤 公彦; 井谷 嘉男; 石橋 徹; 尾熊 隆嘉
日本癌治療学会誌, Aug. 1998, Not refereed

S-2150の血漿中濃度と降圧効果の速度論的解析
石橋 徹, 他
薬物動態, Oct. 1997, Not refereed
Lead

カプトプリルの生体内動態及び薬効に及ぼす外因性SH化合物の影響とその解析
石橋 徹, 他
日本薬学会年会要旨集111年会, Mar. 1991, Not refereed
Lead

クリニカルファーマコメトリクス
辻泰弘; 猪川和朗; 笠井英史, Contributor, 第６章 解析プログラムNONMEM®の基本的な使い方、第７章 解析プログラムNONMEM®を用いたpopulation PKの理解
南山堂, May 2019
9784525723811

新規抗肥満薬であるMGAT2阻害剤S-309309の安全性，忍容性及び薬物動態に関する第１相臨床試験
園山拓洋; 石橋徹; K Safwan; 谷岡秀樹
第44回日本肥満学会学術集会, Nov. 2023, Not invited

Pharmacokinetics of S-309309, A Novel Selective Inhibitor of Monoacylglycerol acyltransferase 2
Ishibashi T.; Tanioka H.; Kezbor S.; Sonoyama T.
Obesity Week 2023, Oct. 2023, Not invited

Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acue Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-CoV-2 Infection
Ishibashi T.; Nomura R.; Shimizu R.; Kubota R.
IDWeek 2023, Oct. 2023, Not invited

バロキサビル マルボキシル代謝物における薬物動態の人種間差に対する遺伝子多型の影響
柴田理沙; 川口菜穂; 窪田竜二; 越道大樹; 石橋徹; 輪嶋恵宏
第42回日本臨床薬理学会学術総会, Dec. 2021, Not invited

Pharmacokinetic and Pharmacodynamic Analysis of S-033188/S-033447, a Novel Inhibitor of Influenza Virus Cap-Endonuclease, in Mice Infected with Influenza A Virus
Noshi T.; Sato K.; Ishibashi T.; Ando Y.; Ueda H.; Oka R.; Kawai M.; Yoshida R.; Sato A.; Shishido T.; Naito A.
27th ECCMID, Apr. 2017, Not invited

Pharmacokinetic/Pharmacodynamic analysis of S-033188, an influenza cap-dependent endonuclease inhibitor, from a phase 2, randomized, double-blind, placebo-controlled study in otherwise healthy adults with seasonal influenza
Watanabe A.; Hirotsu N.; Ishida T.; Ishibashi T.; Kawaguchi K.; Sato C.; Shishido T.; Uehara T.
27th ECCMID, Apr. 2017, Not invited

A phase 1 study of safety, tolerability and pharmacokinetics of oral single dose S-033188, a novel anti-influenza agent, in healthy adult male subjects
Ishibashi T.; Sato C.; Kawasaki A.
IDWeek 2016, Oct. 2016, Not invited

S-033188, a Small Molecule Inhibitor of Cap-dependent Endonuclease of Influenza A and B Virus, Leads to Rapid and Profound Ciral Load Reduction
Uehara U.; Shishido T.; Ishibashi T.; Kawaguchi K.; Sato C.; Ishida T.; Hirotsu N.; Watanabe A.
Options IX for the Control of Influenza Conference, Aug. 2016, Not invited

Dose Adjustment of S-649266, a Siderophore Cephalosporin, for Patients Requiring Hemodialysis
Katsube T.; Wajima T.; Ishibashi T.; Ferreira J CA; Echols R.
26th ECCMID, Apr. 2016, Not invited

S-649266 Dose Adjustment for Patients with Impaired Renal Function
Katsube T.; Wajima T.; Ishibashi T.; Ferreira J CA; Echols R.
25th ECCMID, Apr. 2015, Not invited

S-649266 PK/PD Simulation to Support Dose Selection for Augmented Renal Clearance
Katsube T.; Wajima T.; Ishibashi T.; Ferreira J CA; Echols R.
25th ECCMID, Apr. 2015, Not invited

S-649266 Modeling and Simulation for Prediction of Efficacy and Dose Optimization
Katsube T.; Ishibashi T.; Tenero D.; Wajima W.
IDWeek 2014, Oct. 2014, Not invited

小児通年性アレルギー鼻炎患者におけるロラタジンのPopulation Pharmacokinetics
谷川原祐介; 石橋徹; 石川研介; 吉岡隆之
第39回日本小児臨床薬理学会学術集会, Oct. 2012, Not invited

ドリペネムの母集団薬物動態解析及びモンテカルロシミュレーションによる腎機能障害者における用法用量の検討
石橋徹; 松尾裕美子; 窪田竜二; 輪嶋恵宏
第28回TDM学会学術大会, Jun. 2011, Not invited

Population Pharmacokinetics of Peramivir and Dose Adjustment for Influenza Patients with Renal Impairment
Ishibashi T.; Wajima T.; Matsuo Y.; Holister A.; Kohno S.; Shimada J.
21st ECCMID, May 2011, Not invited

抗インフルエンザ薬ペラミビルの母集団薬物動態パラメータに基づく，腎機能障害者における用量の検討
松尾裕美子; 輪嶋恵宏; 石橋徹; 河野茂; 嶋田甚五郎
第58回日本化学療法学会西日本支部総会, Nov. 2010, Not invited

PVAコポリマーを用いた製剤の安定化研究
船木健至; 吉田達守; 石橋徹; 輪嶋恵宏; 古家喜弘
日本薬学会第128年会, Mar. 2008, Not invited

Accuracy of a Compact Infrared Gas Analyzer for Potent Inhaled Anesthetics
Hendrickx J FA; Saidman L.; Ishibashi T.; Lemmens H.
American Society of Anesthesiologists 2006, Oct. 2006, Not invited

Isoflurane Pharmacokinetics: Linking Lung Uptake to Arterial and Mixed Venous Blood Concentrations
Ishibashi T.; Hendrickx J FA; Wolf AM De; Zundert A AJ Van; Lemmens H.
American Society of Anesthesiologists 2006, Oct. 2006, Not invited

日本人小児患者におけるバンコマイシン母集団パラメータの予測性評価
大西綾子; 矢野義孝; 石橋徹; 勝部孝行; 尾熊隆嘉
第22回TDM学会学術大会, May 2005, Not invited

NONMEMを活用したTDM解析支援ソフトウェアの開発
石橋徹; 矢野育子; 増田智先; 桂敏也; 乾賢一
第22回TDM学会学術大会, May 2005, Not invited

1-compartment modelによるvancomycin母集団薬物動態パラメータの算出
小笠原拓也; 五十嵐正博; 石橋徹; 大西綾子; 中谷龍王; 中田紘一郎; 吉村邦彦; 田口恭治
日本薬学会第124年会, Mar. 2004, Not invited

バンコマイシン TDM 支援ソフトウェア (VCM-TDM) の機能強化
石橋徹; 福村和也; 矢野義孝; 尾熊隆嘉
第10回日本病院薬学会年会, Oct. 2000, Not invited

白金錯体抗癌剤ネダプラチン (アクプラ) の母集団体内動態解析
石橋徹; 矢野義孝; 尾熊隆嘉
第21回日本臨床薬理学会年会, Sep. 2000, Not invited

Nedaplatin (254S) dosage prospective study of new formula
内藤子来; 安藤進; 脇本栄子; 小笠原利忠; 竹村正; 香山浩二; 伊藤公彦; 井谷嘉男; 石橋徹; 尾熊隆嘉
第37回日本癌治療学会総会, Oct. 1999, Not invited

A pharmacokinetic study of nedaplatin(254S)
安達進; 脇本栄子; 金澤理一郎; 小笠原利忠; 竹村正; 香山浩二; 伊藤公彦; 井谷嘉男; 石橋徹; 尾熊隆嘉
第36回日本癌治療学会総会, Oct. 1998, Not invited

S-2150の血漿中濃度と降圧効果の速度論解析
石橋徹; 尾熊隆嘉
第12回日本薬物動態学会総会, Nov. 1997, Not invited

カプトプリルの生体内動態及び薬効に及ぼす外因性SH化合物の影響とその解析
石橋徹; 斎藤昭代; 大森由美; 片山和憲; 掛見正郎; 小泉保
日本薬学会第111年会, Mar. 1991, Not invited

Present
日本薬物動態学会

Present
日本化学療法学会

Present
日本TDM学会